We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Zika Test Authorized by FDA for Emergency Use

By LabMedica International staff writers
Posted on 10 May 2016
Print article
The first test from a commercial lab provider to receive the US Food & Drug Administration (FDA)’s Emergency Use Authorization (EUA) for testing patients in the USA, including Puerto Rico, for Zika infection. The molecular test is intended for the qualitative detection of RNA from the Zika virus in human serum specimens from certain individuals.

Quest Diagnostics (Madison, NJ, USA), leading provider of diagnostic information services, was granted the EUA for the Zika Virus RNA Qualitative Real-Time RT-PCR test (Zika RT-PCR test). The proprietary test was developed by the reference laboratory business of Quest's subsidiary Focus Diagnostics, Inc. This test has not been FDA cleared or approved beyond the EUA designation.

Until now, the only FDA EUA authorized Zika tests were available from the US Centers for Disease Control and Prevention (CDC) and were only used in qualified laboratories designated by the CDC. "The availability of our new molecular Zika test provides physicians broad access to a diagnostic tool for managing the Zika outbreak," said Rick L. Pesano, MD, PhD, vice president, research & development, Quest Diagnostics, "Quest's expertise in molecular, infectious disease, and women's health diagnostics, and relationships with half of the country's physicians and hospitals, allow us to quickly make useful tests widely available for clinical use. This capability uniquely positions Quest to complement the response of public health laboratories for Zika outbreaks where access to FDA-authorized diagnostic tests can potentially influence the quality of patient management."

The EUA authorizes use of the Zika RT-PCR test by qualified laboratories designated by Focus Diagnostics, including potentially at any CLIA high-complexity laboratory in the Quest Diagnostics network. For now, only the Focus Diagnostics reference laboratory in San Juan Capistrano (CA, USA) will perform this test. Quest Diagnostics also plans to offer serological test services assuming FDA-authorization of serological test kits for emergency use.

The Zika RT-PCR test is intended only for qualitative detection of RNA from Zika virus in human serum specimens from patients meeting CDC Zika virus clinical criteria (e.g. clinical signs and symptoms associated with Zika virus infection) and/or CDC Zika virus epidemiological criteria (e.g. history of residence in or travel to a geographic region with active Zika transmission at the time of travel, or other epidemiologic criteria for which Zika virus testing may be indicated).

Within the US, positive results of this test must be reported to CDC. The diagnosis of Zika virus infection must be made based on history, signs, symptoms, exposure likelihood, and other laboratory evidence in addition to identification of Zika virus. Negative results do not preclude Zika virus infection and should not be used as the sole basis for patient management decisions.

Related Links:
Quest Diagnostics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.